Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Bone Cancer

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Bone Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dohi, T; Kitayama, T; Morita, K; Motoyama, N; Shiraishi, S1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Bone Cancer

ArticleYear
[Pain relieving effect of platelet-activating factor (PAF) antagonists in a bone cancer pain model].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2015, Volume: 146, Issue:2

    Topics: Animals; Bone Neoplasms; Disease Models, Animal; Femur; Humans; Morphine; Pain; Pain Management; Palliative Care; Platelet Activating Factor

2015